HIV-1 replication in CD4+ T cell lines: The effects of adaptation on co-receptor use, tropism, and accessory gene function

Journal of Leukocyte Biology

Volumn 68, Issue 3, 2000, Pages 331-337

  Dejucq, N ^a  

^a INSERM   (France)

Author keywords

CCR5; CXCR4; Macrophage and T cell lines tropism; Vpu

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4;

HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS INFECTION; VIRUS REPLICATION;

ADAPTATION, BIOLOGICAL; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; GENES, ENV; GENES, VPU; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033635355     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. The role of viral diversity in HIV pathogenesis
2. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection
3. Resistance, drug failure, and disease progression
4. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population
5. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
6. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates
7. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals
8. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates
9. Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates
10. Macrophage-tropism of HIV-1 isolates of different genetic subtypes
11. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection
12. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1
13. Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages
14. Dual-tropic, primary, syncytium-inducing HIV-1 strains that can use either Lestr or CCR5 as co-receptors for virus entry
15. CXCR4 as a functionnal co-receptor for Human Immunodeficiency Virus type 1 infection of primary macrophages
16. Genotypic and phenotypic characterization of HIV-1 patients with primary infection
17. + cell depletion and progression to AIDS
18. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G-protein coupled receptor
19. + cells is mediated by the chemokine receptor CC-CKR5
20. Identification of a major co-receptor for primary isolates of HIV-1
21. HIV entry and tropism: The chemokine receptor connection
22. Coreceptors: Implications for HIV pathogenesis and therapy
23. Immunodeficiency viruses. Spoilt for choice of co-receptors
24. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1)
25. HIV-1 subtype and second-receptor use
26. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as fusion cofactor for macrophage-tropic HIV-1
27. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
28. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
29. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES
30. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1α, and MIP-1β
31. Molecular cloning and functional expression of a new human CC-chemokine receptor gene
32. Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication
33. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
34. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
35. A new classification for HIV-1
36. The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dual-tropic human immunodeficiency virus type 1
37. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses
38. Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection
39. Chemokines beyond inflammation
40. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains
41. A new SIV co-receptor, STRL33
42. Expression cloning of new receptors used by simian and human immunodeficiency viruses
43. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function
44. Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection
45. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry
46. The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells
47. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: Resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation
48. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1
49. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro
50. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors
51. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways
52. Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors
53. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
54. Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia
55. Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia
56. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
57. + T cells and monocytes from cord and adult blood
58. Inhibition of HIV fusion by a monoclonal antibody to a co-receptor (CXCR4) is both cell type and virus strain dependent
59. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor
60. HIV-1 tropism and co-receptor usage
61. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1
62. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu and nef
63. Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures
64. Chemokine receptors in HIV-1 infection of the central nervous system
65. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism
66. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
67. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages
68. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes
69. Macrophage and T-cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene
70. Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism
71. Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1
72. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype
73. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes
74. Identification of the envelope V3 loop as a determinant of a CD4-negative neuronal cell tropism for HIV-1
75. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop
76. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage
77. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
78. V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate
79. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
80. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor
81. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion
82. Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation
83. Effects of amino acid changes in the V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation and recognition by neutralizing antibody
84. Relation of phenotype evolution of HIV-1 to envelope V2 configuration
85. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization
86. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
87. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop
88. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1
89. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
90. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
91. Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5
92. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1
93. Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1
94. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1
95. Host factors and the pathogenesis of HIV-induced disease
96. Mutations in the vpu, env, and nef genes of a syncytium-inducing variant of HIV type 1 JR-CSF that infects a range of T cell lines
97. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1
98. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers
99. In vivo selected HIV-1 isolate shows altered tropism without shift in co-receptor use
100. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes
101. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants
102. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells
103. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway
104. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner
105. Human immunodeficiency virus type 1 Vpu modifies viral cytopathic effect through augmented virus release
106. Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env
107. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: A Vpu-like factor?
108. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1
109. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
110. Identification of highly attenuated mutants of simian immunodeficiency virus
111. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge